NEW YORK (GenomeWeb News) – Asuragen has raised $7.5 million toward a targeted $15 million round.

The Austin, Texas-based molecular diagnostics firm disclosed the funding in a document filed this week with the US Securities and Exchange Commission. Company President and CEO Rollie Carlson said that existing investors participated in the raise, which will go toward the commercialization of Asuragen's oncology and genetic disease tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.